...conjugate (ADC) technology at its Heidelberg Pharma subsidiary in Ladenburg, Germany (see BioCentury, Feb. 3). IBA Group...

...The management of Cisbio Bioassays S.A.S., a business unit of Ion Beam Applications, completed a buyout of the...
...screening platform in the U.S. and Europe for drug discovery (see BioCentury, Oct. 1, 2012). Ion Beam Applications S.A....

...affairs, decommissioning, waste management and accounting treatments. The remaining amount is still being disputed by Ion Beam Applications...
...other claims have been settled or have become immaterial or waived by SK Capital Partners. Ion Beam Applications S.A....

...screening platform in the U.S. and Europe for drug discovery (see BioCentury, Oct. 1, 2012). Ion Beam Applications S.A....

...Cisbio Bioassays, a member of the IBA group, launched its epigenetics toolbox based on the company's homogenous...
...directly in whole cells, and can be used for the screening of potential anti-cancer compounds. IBA Group...

...evidence of the cancer diagnostic's safety and efficacy. At the time, Wilex and commercialization partner IBA Group...

...evidence of the cancer diagnostic's safety and efficacy. At the time, Wilex and commercialization partner IBA Group...

...Federal Institute for Drugs and Medical Devices recommends against the use of Actos Wilex AG (Xetra:WL6)/IBA Group...

...FDA," Wilhelm said. He declined to give examples of potential endpoints or provide a timeline. IBA Group...
...to diagnose clear RCC and is responsible for radio-labeling the antibody. Companies and Institutions Mentioned IBA Group...

...trial provided reasonable evidence of the cancer diagnostic's safety and efficacy. Wilex and commercialization partner IBA Group...